Versanis Bio’s Bimagrumab Shows Improvement in Weight Loss Patients

Versanis Bio’s Bimagrumab Shows Improvement in Weight Loss Patients

Versanis Bio, a clinical-stage biopharmaceutical company based in New York, announced the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients. The, obtained from pooling data across five previously completed Phase II studies, showed that 24 weeks of intravenous bimagrumab treatment at the highest …

Versanis Bio’s Bimagrumab Shows Improvement in Weight Loss Patients Read More »